David Bailey Buys 31,500 Shares of KindlyMD (NASDAQ:NAKA) Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey purchased 31,500 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were purchased at an average price of $5.58 per share, with a total value of $175,770.00. Following the completion of the acquisition, the chief executive officer directly owned 3,015,528 shares in the company, valued at $16,826,646.24. The trade was a 1.06% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

KindlyMD Trading Up 11.8%

Shares of NASDAQ NAKA opened at $6.26 on Friday. KindlyMD, Inc. has a 12 month low of $4.50 and a 12 month high of $995.60. The firm has a market capitalization of $108.92 million, a PE ratio of -0.14 and a beta of 17.12. The firm has a fifty day simple moving average of $8.14 and a two-hundred day simple moving average of $13.02.

KindlyMD (NASDAQ:NAKA) last released its earnings results on Wednesday, May 13th. The company reported ($15.20) earnings per share for the quarter. The business had revenue of $2.68 million during the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%. On average, sell-side analysts predict that KindlyMD, Inc. will post -16.8 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on NAKA shares. Wall Street Zen upgraded shares of KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. B. Riley Financial lowered their target price on shares of KindlyMD from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. Weiss Ratings upgraded shares of KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. TD Cowen started coverage on shares of KindlyMD in a research note on Friday, April 10th. They set a “buy” rating and a $40.00 target price on the stock. Finally, Maxim Group lowered their target price on shares of KindlyMD from $60.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, KindlyMD currently has a consensus rating of “Hold” and an average target price of $30.00.

More KindlyMD News

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David Bailey bought 31,500 more shares at $5.58, adding to a recent series of insider purchases that may reassure investors about the company’s outlook. Article Title
• Positive Sentiment: Maxim Group reiterated a Buy rating on NAKA with a $30 price target, and its newer earnings forecasts imply a possible improvement in results over time. Article Title
• Neutral Sentiment: The analyst estimates still call for losses in the next several quarters, though they show a potential path toward profitability in fiscal 2027. Article Title
• Negative Sentiment: KindlyMD’s latest reported quarter showed a large EPS loss and very weak profitability, underscoring that the business remains highly speculative despite the recent stock strength. Article Title

Institutional Trading of KindlyMD

Institutional investors and hedge funds have recently modified their holdings of the company. Alyeska Investment Group L.P. bought a new stake in shares of KindlyMD during the fourth quarter valued at approximately $8,993,000. ParaFi Capital LP bought a new stake in shares of KindlyMD during the third quarter valued at approximately $443,055,000. Hunting Hill Global Capital LLC bought a new stake in shares of KindlyMD during the fourth quarter valued at approximately $4,672,000. RK Capital Management LLC FL bought a new stake in shares of KindlyMD during the third quarter valued at approximately $239,052,000. Finally, Yorkville Advisors Global LP bought a new stake in shares of KindlyMD during the third quarter valued at approximately $231,942,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.